Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02607774 · ClinicalTrials.gov registry record · Phase 1
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02607774 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT02607774, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Midazolam
- DRUG AIN457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-12-17 |
| Est. Completion | 2016-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02607774
The ClinicalTrials.gov registry entry for NCT02607774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT02607774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02607774 about?
NCT02607774 is a clinical study titled "Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis". To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT02607774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-12-17. Estimated completion is 2016-12-20.
What interventions are being tested in trial NCT02607774?
The interventions under investigation include: Midazolam (DRUG), AIN457 (DRUG).
Who is sponsoring clinical trial NCT02607774?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.